Analysis of DNA changes in the LPL gene in patients with familial combined hyperlipidemia

E. Gagné, J. Genest, Hanfang Zhang, L. A. Clarke, M. R. Hayden

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

Familial combined hyperlipidemia (FCHL) is a common lipid disorder characterized by an increase in cholesterol and/or triglyceride levels in multiple individuals of the same family. Prior reports document a decreased activity of lipoprotein lipase (LPL) in FCHL, and studies of the role of LPL in the remodeling of nascent lipoproteins suggest that disturbances in LPL function could underlie FCHL. We studied the LPL gene in 31 unrelated individuals with FCHL. A total of 25 DNA changes (13 "silent" substitutions and 12 DNA changes resulting in amino acid substitutions) were detected in 16 patients. Three new exonic polymorphisms as well as a previously described Ser447→stop and an Asp9→Asn substitution were seen with similar frequency on control and FCHL chromosomes. Two novel DNA changes resulting in an Asp21→Val and an His44→Tyr substitution were seen in only two FCHL individuals. In vitro studies showed no effect of these mutations on LPL catalytic activity. LPL mutations impairing catalytic activity did not represent a significant factor leading to FCHL in this population. Variations in any portion of the coding region of the LPL gene affecting other functions besides catalysis are not a frequent cause of FCHL.

Original languageEnglish (US)
Pages (from-to)1250-1257
Number of pages8
JournalArteriosclerosis, thrombosis, and vascular biology
Volume14
Issue number8
DOIs
StatePublished - Jan 1 1994

Fingerprint

Familial Combined Hyperlipidemia
Lipoprotein Lipase
DNA
Genes
Mutation
Amino Acid Substitution
Catalysis
Lipoproteins
Triglycerides
Chromosomes
Cholesterol
Lipids

Keywords

  • DNA changes
  • Lipoprotein lipase
  • Molecular genetics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Analysis of DNA changes in the LPL gene in patients with familial combined hyperlipidemia. / Gagné, E.; Genest, J.; Zhang, Hanfang; Clarke, L. A.; Hayden, M. R.

In: Arteriosclerosis, thrombosis, and vascular biology, Vol. 14, No. 8, 01.01.1994, p. 1250-1257.

Research output: Contribution to journalArticle

Gagné, E. ; Genest, J. ; Zhang, Hanfang ; Clarke, L. A. ; Hayden, M. R. / Analysis of DNA changes in the LPL gene in patients with familial combined hyperlipidemia. In: Arteriosclerosis, thrombosis, and vascular biology. 1994 ; Vol. 14, No. 8. pp. 1250-1257.
@article{521faa41107f48db837b20af231624b4,
title = "Analysis of DNA changes in the LPL gene in patients with familial combined hyperlipidemia",
abstract = "Familial combined hyperlipidemia (FCHL) is a common lipid disorder characterized by an increase in cholesterol and/or triglyceride levels in multiple individuals of the same family. Prior reports document a decreased activity of lipoprotein lipase (LPL) in FCHL, and studies of the role of LPL in the remodeling of nascent lipoproteins suggest that disturbances in LPL function could underlie FCHL. We studied the LPL gene in 31 unrelated individuals with FCHL. A total of 25 DNA changes (13 {"}silent{"} substitutions and 12 DNA changes resulting in amino acid substitutions) were detected in 16 patients. Three new exonic polymorphisms as well as a previously described Ser447→stop and an Asp9→Asn substitution were seen with similar frequency on control and FCHL chromosomes. Two novel DNA changes resulting in an Asp21→Val and an His44→Tyr substitution were seen in only two FCHL individuals. In vitro studies showed no effect of these mutations on LPL catalytic activity. LPL mutations impairing catalytic activity did not represent a significant factor leading to FCHL in this population. Variations in any portion of the coding region of the LPL gene affecting other functions besides catalysis are not a frequent cause of FCHL.",
keywords = "DNA changes, Lipoprotein lipase, Molecular genetics",
author = "E. Gagn{\'e} and J. Genest and Hanfang Zhang and Clarke, {L. A.} and Hayden, {M. R.}",
year = "1994",
month = "1",
day = "1",
doi = "10.1161/01.ATV.14.8.1250",
language = "English (US)",
volume = "14",
pages = "1250--1257",
journal = "Arteriosclerosis, Thrombosis, and Vascular Biology",
issn = "1079-5642",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Analysis of DNA changes in the LPL gene in patients with familial combined hyperlipidemia

AU - Gagné, E.

AU - Genest, J.

AU - Zhang, Hanfang

AU - Clarke, L. A.

AU - Hayden, M. R.

PY - 1994/1/1

Y1 - 1994/1/1

N2 - Familial combined hyperlipidemia (FCHL) is a common lipid disorder characterized by an increase in cholesterol and/or triglyceride levels in multiple individuals of the same family. Prior reports document a decreased activity of lipoprotein lipase (LPL) in FCHL, and studies of the role of LPL in the remodeling of nascent lipoproteins suggest that disturbances in LPL function could underlie FCHL. We studied the LPL gene in 31 unrelated individuals with FCHL. A total of 25 DNA changes (13 "silent" substitutions and 12 DNA changes resulting in amino acid substitutions) were detected in 16 patients. Three new exonic polymorphisms as well as a previously described Ser447→stop and an Asp9→Asn substitution were seen with similar frequency on control and FCHL chromosomes. Two novel DNA changes resulting in an Asp21→Val and an His44→Tyr substitution were seen in only two FCHL individuals. In vitro studies showed no effect of these mutations on LPL catalytic activity. LPL mutations impairing catalytic activity did not represent a significant factor leading to FCHL in this population. Variations in any portion of the coding region of the LPL gene affecting other functions besides catalysis are not a frequent cause of FCHL.

AB - Familial combined hyperlipidemia (FCHL) is a common lipid disorder characterized by an increase in cholesterol and/or triglyceride levels in multiple individuals of the same family. Prior reports document a decreased activity of lipoprotein lipase (LPL) in FCHL, and studies of the role of LPL in the remodeling of nascent lipoproteins suggest that disturbances in LPL function could underlie FCHL. We studied the LPL gene in 31 unrelated individuals with FCHL. A total of 25 DNA changes (13 "silent" substitutions and 12 DNA changes resulting in amino acid substitutions) were detected in 16 patients. Three new exonic polymorphisms as well as a previously described Ser447→stop and an Asp9→Asn substitution were seen with similar frequency on control and FCHL chromosomes. Two novel DNA changes resulting in an Asp21→Val and an His44→Tyr substitution were seen in only two FCHL individuals. In vitro studies showed no effect of these mutations on LPL catalytic activity. LPL mutations impairing catalytic activity did not represent a significant factor leading to FCHL in this population. Variations in any portion of the coding region of the LPL gene affecting other functions besides catalysis are not a frequent cause of FCHL.

KW - DNA changes

KW - Lipoprotein lipase

KW - Molecular genetics

UR - http://www.scopus.com/inward/record.url?scp=0028167760&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028167760&partnerID=8YFLogxK

U2 - 10.1161/01.ATV.14.8.1250

DO - 10.1161/01.ATV.14.8.1250

M3 - Article

VL - 14

SP - 1250

EP - 1257

JO - Arteriosclerosis, Thrombosis, and Vascular Biology

JF - Arteriosclerosis, Thrombosis, and Vascular Biology

SN - 1079-5642

IS - 8

ER -